I love consumer instinct.
Thank you, Peter Lynch, for teaching us about using our instincts as consumers along with megatrends and technical analysis.
Last night we went to a dinner party and the conversation turned to Bowling Green, Nebraska, the Ozempic capital of the U.S.
On December 2, 2024, I wrote a Daily called, Novo-Nordisk, A Love Story.
I wrote, “According to an article in the NY Post, the diet drugs have “changed the foods we eat, the ways we celebrate, and exercise, and travel, and dress, and talk about health and beauty.”
It behooves you to investigate which companies are related to the life changing characteristics the article mentions.
I have been on this theme since 2023 and now have it as one of my major investment themes for 2025.”
As Novo Nordisk (NVO) recently had positive news on a trial about its impact on kidney disease, the stock then gapped up, and then sold off back to major support.
When folks are talking about the drug at dinner parties, and the fundamentals are intact, we get interested.
It is also possible, NVO is offering us another low-risk trade setup.
The Daily chart shows us that even after the gap higher, the price could not hold above the January 6-month calendar range.
However, the move lower has kept price above the calendar range low.
I like the momentum holding up despite the selloff.
And should NVO get back above 85.00, that would look solid.
On the weekly chart, we can clearly see the risk to under the 200-week moving average.
Plus, in the last 2 weeks, NVO has been trading inside the bar from 3 weeks ago.
The monthly chart has its own narrative.
This chart has the 23-month and 80-month moving averages.
While the price is in the middle of both moving averages, note the relative strength on the bottom of the chart.
NVO on a monthly timeframe is massively oversold.
If you add the low risk illustrated on the weekly chart, along with the rising momentum and calendar ranges on the daily chart, that is compelling enough.
That a hot company with good fundamentals is oversold is yet another reason to keep this one on your radar.
Twitter: @marketminute
The author may have a position in mentioned securities at the time of publication. Any opinions expressed herein are solely those of the author and do not represent the views or opinions of any other person or entity.
